Fiduciary Trust Co Has $7.33 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Fiduciary Trust Co reduced its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 2.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 229,801 shares of the company’s stock after selling 6,265 shares during the period. Fiduciary Trust Co owned 0.18% of Apellis Pharmaceuticals worth $7,333,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of APLS. Teacher Retirement System of Texas grew its stake in Apellis Pharmaceuticals by 9.4% in the 4th quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company’s stock valued at $691,000 after buying an additional 1,864 shares during the last quarter. KBC Group NV grew its position in shares of Apellis Pharmaceuticals by 3,862.3% in the fourth quarter. KBC Group NV now owns 104,287 shares of the company’s stock valued at $3,328,000 after purchasing an additional 101,655 shares during the last quarter. Entropy Technologies LP bought a new position in shares of Apellis Pharmaceuticals during the fourth quarter worth approximately $445,000. Barclays PLC lifted its holdings in Apellis Pharmaceuticals by 18.0% during the 3rd quarter. Barclays PLC now owns 255,897 shares of the company’s stock worth $7,381,000 after purchasing an additional 39,019 shares during the last quarter. Finally, Merit Financial Group LLC bought a new stake in Apellis Pharmaceuticals in the 4th quarter valued at $254,000. 96.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Scotiabank lowered their price objective on Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating on the stock in a research report on Thursday. Raymond James cut shares of Apellis Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and dropped their price objective for the stock from $75.00 to $52.00 in a research note on Friday. JPMorgan Chase & Co. raised their target price on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, March 4th. Robert W. Baird cut their price target on Apellis Pharmaceuticals from $55.00 to $47.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Wells Fargo & Company reduced their price target on Apellis Pharmaceuticals from $30.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Thursday. Nine equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.37.

Apellis Pharmaceuticals Stock Performance

NASDAQ APLS opened at $17.30 on Friday. The firm’s fifty day moving average price is $21.31 and its two-hundred day moving average price is $27.12. The stock has a market cap of $2.17 billion, a PE ratio of -8.52 and a beta of 0.73. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.65 and a fifty-two week high of $43.99.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.38). The firm had revenue of $149.90 million for the quarter, compared to the consensus estimate of $197.61 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company’s revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.54) EPS. On average, equities analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total transaction of $139,781.90. Following the sale, the general counsel now directly owns 138,730 shares of the company’s stock, valued at $3,482,123. The trade was a 3.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 6,115 shares of company stock worth $154,684. Insiders own 6.50% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).